Results 81 to 90 of about 180 (117)

Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets

Multiple Sclerosis and Related Disorders, 2022
Yamout, Bassem I, Rieckmann, Peter, Centonze, Diego, Giovannoni, Gavin, Hua, Le H., Oreja-Guevara, Celia, Selchen, Daniel, Sørensen, Per Soelberg, Vermersch, Patrick, Wiendl, Heinz   +9 more
openaire   +1 more source

Safety of cladribine tablets in the treatment of patients with multiple sclerosis

Background: Treating patients with relapsing multiple sclerosis (MS) with cladribine tablets (two times 4 or 5 days of treatment each year for 2 years) results in long-lasting efficacy, with continued stability in many patients for 4 or more years.
Cook, Stuart, Leist, Thomas, Comi, Giancarlo||, Montalban, Xavier||, Giovannoni, Gavin||, Nolting, Axel, Hicking, Christine, Galazka, Andrew, Sylvester, Elke   +8 more
openaire   +1 more source

Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION Study

Clinical Epidemiology
Jan Hillert,1 Helmut Butzkueven,2,3 Melinda Magyari,4 Stig Wergeland,5,6 Nicholas Moore,7 Merja Soilu-Hänninen,8 Tjalf Ziemssen,9 Jens Kuhle,10 Luigi Pontieri,11 Lars Forsberg,1 Jan Harald Aarseth,5 Chao Zhu,2 Nicholas Sicignano,12 Vasili Mushnikov,13 ...
Hillert J, Butzkueven H, Magyari M, Wergeland S, Moore N, Soilu-Hänninen M, Ziemssen T, Kuhle J, Pontieri L, Forsberg L, Aarseth JH, Zhu C, Sicignano N, Mushnikov V, Bezemer I, Sabidó M   +15 more
doaj  

PND64 - COST-EFFECTIVENESS OF CLADRIBINE TABLETS FOR TREATMENT OF RRMS IN THE NETHERLANDS [PDF]

Value in Health, 2018
M. de Francesco, K Mahajan, RE Michels, K Schiffers, S Budhia, G Harty, M Krol   +6 more
openaire   +1 more source

Portuguese consensus for the use of cladribine tablets in multiple sclerosis

Neurodegenerative Disease Management
João de Sá, Mariana Santos, Sónia Batista   +2 more
openaire   +1 more source

Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study [PDF]

Multiple Sclerosis Journal, 2011
Background: Cladribine is a synthetic deoxyadenosine analogue in development as an oral multiple sclerosis (MS) therapy. Objective: To report in detail the safety findings from the 96-week, phase III, double-blind CLARITY study, which evaluated treatment with cladribine tablets in relapsing–remitting MS.
Giancarlo Comi, K Rammohan, P Rieckmann   +2 more
exaly   +3 more sources

COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update [PDF]

Multiple Sclerosis and Related Disorders, 2021
We previously summarized outcomes for 46 cladribine tablets (CladT)-treated patients with multiple sclerosis (MS) and confirmed or suspected COVID-19, as reported to the Merck KGaA Global Patient Safety Database. This report updates on these findings, to 15 January 2021, for a total of 272 reported cases of COVID-19 among CladT recipients.Case ...
Doris Damian, Axel Nolting
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

PO135 Cladribine tablets in rrms: lymphocyte counts

Journal of Neurology, Neurosurgery & Psychiatry, 2017
Background The most common adverse event in CLARITY was lymphopenia, consistent with cladribine tablets (CT) mechanism of action. Objective Investigate absolute lymphocyte count (ALC) in RRMS patients receiving CT 3.5 mg/kg (CT3.5). Methods Patients randomised to CT3.5 for 2 years in CLARITY/CLARITY Extension including time in PREMIERE (n=685 ...
Per Soelberg-Sorensen, Fernando Dangond, Christine Hicking, Gavin Giovannoni   +3 more
  +5 more sources

MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study

Journal of Neurology, 2012
We herein provide a comprehensive assessment of magnetic resonance imaging (MRI) outcomes from CLARITY, a 96-week, double-blind study demonstrating significant clinical and MRI improvements in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets.
Gavin Giovannoni, Per Soelberg Sorensen, Giancarlo Comi   +2 more
exaly   +4 more sources

Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis [PDF]

Multiple Sclerosis and Related Disorders, 2019
Treating patients with relapsing multiple sclerosis (MS) with cladribine tablets (two times 4 or 5 days of treatment each year for 2 years) results in long-lasting efficacy, with continued stability in many patients for 4 or more years. Safety and tolerability outcomes from individual clinical studies with cladribine tablets have been reported ...
Gavin Giovannoni, Xavier Montalbán, Giancarlo Comi   +2 more
exaly   +4 more sources